Omeros Corp (OMER)

16.32
NASDAQ : Health Care
Prev Close 16.47
Day Low/High 16.08 / 16.57
52 Wk Low/High 7.20 / 17.19
Avg Volume 600.50K
Exchange NASDAQ
Shares Outstanding 43.94M
Market Cap 723.67M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: OncoMed, Incyte, Omeros

Biotech Movers: OncoMed, Incyte, Omeros

OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.

Freeport McMoRan, Wix, Zions Bancorporation: 'Mad Money' Lightning Round

Freeport McMoRan, Wix, Zions Bancorporation: 'Mad Money' Lightning Round

Jim Cramer says hold off before jumping into Freeport McMoRan, Wix.com and Zions Bancorporation.

Fed Crashes the Party: Cramer's 'Mad Money' Recap (Wednesday 4/5/17)

Fed Crashes the Party: Cramer's 'Mad Money' Recap (Wednesday 4/5/17)

Jim Cramer stresses discipline here because, he says, a frothy market can quickly turn on investors.

The Dip Buyers Aren't Delivering Much Right Now

The Dip Buyers Aren't Delivering Much Right Now

The indices are holding key support, but this isn't translating into any real momentum.

Omeros To Present At The Needham Healthcare Conference

Omeros To Present At The Needham Healthcare Conference

Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.

Biotech Premarket Movers: Halozyme, Omeros, Aralez

Biotech Premarket Movers: Halozyme, Omeros, Aralez

Halozyme Therapeutics, Omeros and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Omeros Reports More Positive Data In OMS721 Phase 2 Trial In Renal Diseases

Omeros Reports More Positive Data In OMS721 Phase 2 Trial In Renal Diseases

Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the company's Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, which frequently lead to end-stage renal disease...

Noteworthy Tuesday Option Activity: OMER, STOR, RRGB

Noteworthy Tuesday Option Activity: OMER, STOR, RRGB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 4,225 contracts have traded so far, representing approximately 422,500 underlying shares. That amounts to about 75.1% of OMER's average daily trading volume over the past month of 562,750 shares.

Omeros Announces OMS721 Presentation At Annual Meeting of The European Society For Blood And Marrow Transplantation

Omeros Announces OMS721 Presentation At Annual Meeting of The European Society For Blood And Marrow Transplantation

Omeros Corporation (NASDAQ: OMER) today announced presentation of a case report describing resolution of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a dialysis- and...

Omeros To Present Results From Dose-Ranging Stage Of OMS721 Clinical Trial In Atypical Hemolytic Uremic Syndrome At World Congress Of Nephrology

Omeros To Present Results From Dose-Ranging Stage Of OMS721 Clinical Trial In Atypical Hemolytic Uremic Syndrome At World Congress Of Nephrology

Omeros Corporation (NASDAQ: OMER) today announced that data from the dose-ranging stage of the Phase 2 clinical trial evaluating OMS721 in the treatment of atypical hemolytic uremic syndrome (aHUS) will be presented next...

Health Care Vote: Bad Medicine for Market?

I don't understand why this is considered a make-or-break moment.

First Week of November 17th Options Trading For Omeros (OMER)

First Week of November 17th Options Trading For Omeros (OMER)

Investors in Omeros Corp saw new options begin trading this week, for the November 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Omeros Corporation Reports Fourth Quarter And Year-End 2016 Financial Results

Omeros Corporation Reports Fourth Quarter And Year-End 2016 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

These heavily shorted stocks could get squeezed higher if they report positive earnings this week.

Omeros Corporation To Announce Fourth Quarter And Year-End 2016 Financial Results On March 16, 2017

Omeros Corporation To Announce Fourth Quarter And Year-End 2016 Financial Results On March 16, 2017

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2016 financial results for the period ended December 31, 2016, on Thursday, March 16, 2017, after the market...

Commit To Purchase Omeros Corp At $8, Earn 14.1% Annualized Using Options

Commit To Purchase Omeros Corp At $8, Earn 14.1% Annualized Using Options

Investors considering a purchase of Omeros Corp shares, but tentative about paying the going market price of $11.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $8 strike, which has a bid at the time of this writing of 50 cents.

3 Small Biotechs That Still Have Upside

3 Small Biotechs That Still Have Upside

Companies developing drugs for cancer, eye problems and pets -- offer untapped value.

Omeros To Present At The Cowen And Company Annual Health Care Conference

Omeros To Present At The Cowen And Company Annual Health Care Conference

Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.

Omeros Reports Additional Positive Results From OMS721 Phase 2 Trial In Patients With Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Reports Additional Positive Results From OMS721 Phase 2 Trial In Patients With Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the ongoing Phase 2 clinical trial evaluating OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic...

Omeros is Now Oversold (OMER)

Omeros is Now Oversold (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Data From Omeros' OMS721 Phase 2 Clinical Trial In Patients With Stem Cell Transplant-Associated TMA To Be Presented At International Transplant Conference

Data From Omeros' OMS721 Phase 2 Clinical Trial In Patients With Stem Cell Transplant-Associated TMA To Be Presented At International Transplant Conference

Omeros Corporation (NASDAQ: OMER) today announced that an abstract highlighting positive results from the ongoing OMS721 Phase 2 clinical trial in patients with hematopoietic stem cell transplant-associated thrombotic...

Omeros Extending Compassionate Use For Pediatric Patient No Longer Requiring Dialysis After OMS721 Treatment

Omeros Extending Compassionate Use For Pediatric Patient No Longer Requiring Dialysis After OMS721 Treatment

Omeros Corporation (NASDAQ: OMER) today announced that, following physician request, it will provide continued supply of OMS721 for a pediatric patient with hematopoietic stem cell transplant-associated thrombotic...

First Week of OMER January 2017 Options Trading

First Week of OMER January 2017 Options Trading

Investors in Omeros Corp saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.

Omeros' Proprietary Orphan GPCR Program Delivers New Target And Approach In Cancer Immunotherapy

Omeros' Proprietary Orphan GPCR Program Delivers New Target And Approach In Cancer Immunotherapy

Omeros Corporation (NASDAQ: OMER) today announced that its small-molecule inhibitors against GPR174, an orphan G protein-coupled receptor (GPCR) narrowly expressed in immune cells and linked to cancers, substantially and...

International Consortium Of Complement Experts Receives €1.3 Million Grant To Study Role Of MASP-2 And Lectin Pathway In Traumatic Brain Injury

International Consortium Of Complement Experts Receives €1.3 Million Grant To Study Role Of MASP-2 And Lectin Pathway In Traumatic Brain Injury

Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy, United Kingdom, Germany, Spain and Poland was awarded €1.

Omeros Announces Successful Outcome Of OMIDRIA® Pediatric Cataract Trial

Omeros Announces Successful Outcome Of OMIDRIA® Pediatric Cataract Trial

Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA ® (phenylephrine and ketorolac injection) 1% / 0.

Single Dose Of Omeros' Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade Of The Alternative Pathway

Single Dose Of Omeros' Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade Of The Alternative Pathway

Omeros Corporation (NASDAQ: OMER) today announced pharmacokinetic and pharmacodynamic data from the evaluation of OMS906 in non-human primates.

Omeros Corporation Reports Third Quarter 2016 Financial Results

Omeros Corporation Reports Third Quarter 2016 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...